
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7408239/publications.pdf Version: 2024-02-01



<u>Ερις ΤρÃΩρο</u>

#	Article	IF	CITATIONS
1	Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2022, 20, 651-657.	4.4	3
2	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	3.7	33
3	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	10.7	36
4	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. Gut, 2022, 71, 1856-1866.	12.1	17
5	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 1038-1046.	3.7	17
6	Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer, 2022, 11, 460-473.	7.7	13
7	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. Cancer Discovery, 2021, 11, 2524-2543.	9.4	41
8	Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. Oncogene, 2021, 40, 5155-5167.	5.9	30
9	Combination of Model for Endâ€Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. Hepatology, 2021, 74, 2085-2101.	7.3	25
10	Clinical Course and Risk Factors for Infection in Severe Forms of Alcoholâ€Associated Liver Disease. Hepatology, 2021, 74, 2714-2724.	7.3	12
11	REPLY:. Hepatology, 2021, 74, 2927-2928.	7.3	0
12	Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered. Journal of Hepatology, 2021, 75, 989-990.	3.7	9
13	The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites. JHEP Reports, 2021, 3, 100319.	4.9	3
14	Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study. Endoscopy International Open, 2021, 09, E1792-E1800.	1.8	5
15	Gene signatureâ€MELD score and alcohol relapse determine longâ€ŧerm prognosis of patients with severe alcoholic hepatitis. Liver International, 2020, 40, 565-570.	3.9	12
16	Histologic parameter score does not predict shortâ€ŧerm survival in severe alcoholic hepatitis. United European Gastroenterology Journal, 2020, 8, 1003-1012.	3.8	12
17	Noninvasive diagnosis in alcoholâ€related liver disease. Health Science Reports, 2020, 3, e146.	1.5	8
18	Update on NAFLD genetics: From new variants to the clinic. Journal of Hepatology, 2020, 72, 1196-1209.	3.7	234

#	Article	IF	CITATIONS
19	Epigenetic basis for monocyte dysfunction in patients with severe alcoholic hepatitis. Journal of Hepatology, 2020, 73, 303-314.	3.7	24
20	Perturbations in Mitochondrial Dynamics Are Closely Involved in the Progression of Alcoholic Liver Disease. Alcoholism: Clinical and Experimental Research, 2020, 44, 856-865.	2.4	21
21	Long-term outcomes in patients with decompensated alcohol-related liver disease, steatohepatitis and Maddrey's discriminant function <32. Journal of Hepatology, 2020, 72, 636-642.	3.7	43
22	Vasomodulators and Liver Transplantation for Portopulmonary Hypertension: Evidence From a Systematic Review and Metaâ€Analysis. Hepatology, 2020, 72, 1701-1716.	7.3	27
23	Combination of meld and lactates predicts early death in patients treated by salvage tips for refractory variceal bleeding. Journal of Hepatology, 2020, 73, S693.	3.7	0
24	Systematic review with metaâ€analysis: automated lowâ€flow ascites pump therapy for refractory ascites. Alimentary Pharmacology and Therapeutics, 2019, 50, 978-987.	3.7	21
25	A 17â€Betaâ€Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240.	7.3	75
26	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	5.1	72
27	The prognostic value of acute-on-chronic liver failure during the course of severe alcoholic hepatitis. Journal of Hepatology, 2018, 69, 318-324.	3.7	82
28	Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach. Journal of Hepatology, 2018, 68, 1322-1323.	3.7	3
29	Combination of Gene Expression Signature and Model for End-Stage Liver Disease Score Predicts Survival of Patients WithÂSevere Alcoholic Hepatitis. Gastroenterology, 2018, 154, 965-975.	1.3	41
30	Epidemiology and Elimination of HCV-Related Liver Disease. Viruses, 2018, 10, 545.	3.3	48
31	Liver transplantation for alcoholic hepatitis: A systematic review with meta-analysis. PLoS ONE, 2018, 13, e0190823.	2.5	75
32	JNK Activation of BIM Promotes Hepatic Oxidative Stress, Steatosis, and Insulin Resistance in Obesity. Diabetes, 2017, 66, 2973-2986.	0.6	21
33	Liver stiffness and platelet count for identifying patients with compensated liver disease at low risk of variceal bleeding. Liver International, 2017, 37, 707-716.	3.9	70
34	Insulin resistance is associated with esophageal varices in alcoholic liver disease patients. European Journal of Gastroenterology and Hepatology, 2016, 28, 792-796.	1.6	6
35	Serum βâ€lactam concentrations in critically ill patients with cirrhosis: a matched case–control study. Liver International, 2016, 36, 1002-1010.	3.9	12
36	Alcohol intake increases the risk of HCC in hepatitis C virus-related compensated cirrhosis: A prospective study. Journal of Hepatology, 2016, 65, 543-551.	3.7	67

#	Article	IF	CITATIONS
37	PNPLA3 gene in liver diseases. Journal of Hepatology, 2016, 65, 399-412.	3.7	205
38	Reply. Gastroenterology, 2016, 151, 377.	1.3	0
39	Intensive Enteral Nutrition Is Ineffective for Patients With Severe Alcoholic Hepatitis Treated With Corticosteroids. Gastroenterology, 2016, 150, 903-910.e8.	1.3	131
40	Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1074-1079.	1.6	52
41	Early transjugular intrahepatic portosystemic shunt in cirrhotic patients with acute variceal bleeding. European Journal of Gastroenterology and Hepatology, 2015, 27, e1-e9.	1.6	70
42	The use of betaâ€blockers is associated with the occurrence of acute kidney injury in severe alcoholic hepatitis. Liver International, 2015, 35, 1974-1982.	3.9	39
43	Combining Data From Liver Disease Scoring Systems Better Predicts Outcomes of Patients With Alcoholic Hepatitis. Gastroenterology, 2015, 149, 398-406.e8.	1.3	134
44	A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nature Genetics, 2015, 47, 1443-1448.	21.4	435
45	PNPLA3 genetic variation in alcoholic steatosis and liver disease progression. Hepatobiliary Surgery and Nutrition, 2015, 4, 152-60.	1.5	8
46	Correction of allâ€ŧrans retinoic acid deficiency in alcoholic cirrhosis lessens the excessive inflammatory monocyte response: a translational study. Liver International, 2014, 34, 343-352.	3.9	9
47	Reply. Hepatology, 2014, 60, 1111-1112.	7.3	0
48	Association between the <i>PNPLA3</i> (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data. Hepatology, 2014, 59, 2170-2177.	7.3	193
49	Invasive aspergillosis in patients with severe alcoholic hepatitis. Journal of Hepatology, 2014, 60, 267-274.	3.7	113
50	Microsatellite polymorphism in the heme oxygenase-1 gene promoter is not associated with alcoholic liver disease severity. Hepatology, 2014, 59, 352-353.	7.3	2
51	Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease. Journal of Hepatology, 2013, 59, 344-350.	3.7	101
52	Liver transplantation for alcoholic liver disease: a retrospective analysis of recidivism, survival and risk factors predisposing to alcohol relapse. Acta Gastro-Enterologica Belgica, 2013, 76, 282-90.	1.0	9
53	The ST2 Pathway Is Involved in Acute Pancreatitis. American Journal of Pathology, 2012, 180, 2330-2339.	3.8	27
54	Reply to: "Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patientsâ€: Journal of Hepatology, 2012, 56, 1210-1212.	3.7	4

#	Article	IF	CITATIONS
55	Hepatocytes That Express Variants of Cyclophilin A Are Resistant to HCV Infection and Replication. Gastroenterology, 2012, 143, 439-447.e1.	1.3	30
56	N-glycan based biomarker distinguishing non-alcoholic steatohepatitis from steatosis independently of fibrosis. Digestive and Liver Disease, 2012, 44, 315-322.	0.9	37
57	<i>PNPLA3</i> (rs738409 C>C) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis. Hepatology, 2012, 55, 1307-1308.	7.3	69
58	Metaâ€analysis: the impact of <scp>IL</scp> 28 <scp>B</scp> polymorphisms on rapid and sustained virological response in <scp>HCV</scp> â€2 and â€3 patients. Alimentary Pharmacology and Therapeutics, 2012, 36, 353-362.	3.7	37
59	Hepatic expression of CCL2 in alcoholic liver disease is associated with disease severity and neutrophil infiltrates. Clinical and Experimental Immunology, 2012, 169, 302-310.	2.6	46
60	Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. Journal of Hepatology, 2011, 55, 38-44.	3.7	51
61	Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. Journal of Hepatology, 2011, 55, 906-912.	3.7	138
62	Reply to: "Modulation of the effect of PNPLA3 I148M mutation on steatosis and liver damage by alcohol intake in patients with chronic hepatitis C― Journal of Hepatology, 2011, 55, 1471-1472.	3.7	5
63	Association of <i>PNPLA3</i> (rs738409 C>C) with liver damage in liver diseases: one step closer to personalized medicine?. Personalized Medicine, 2011, 8, 595-597.	1.5	5
64	Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 2011, 54, 60-69.	7.3	166
65	The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology, 2010, 51, 356-357.	7.3	13
66	749 Role of the Cirrhosis Risk Score (CRS) for the Prediction of Fibrosis Progression in Hepatitis C Patients with Minimal Liver Disease. Gastroenterology, 2009, 136, A-806.	1.3	1
67	Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroenterologie Clinique Et Biologique, 2008, 32, 858-865.	0.9	14
68	Chylorrhea after axillary lymph node dissection. European Journal of Surgical Oncology, 2007, 33, 1042-1043.	1.0	11